Pfizer checks if migraine drug versions match up

NCT ID NCT07261371

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested four different formulations of a CGRP receptor antagonist, a drug used for migraines, in 64 healthy adults. The goal was to see if the different versions are absorbed and processed by the body in the same way. This is a Phase 1 trial, so it focuses on safety and how the drug behaves, not on treating a condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

calcitonin gene-related peptide receptor inhibitor

What this could lead to

If successful, this could help ensure that different versions of this migraine medication are equally effective and safe.

What could go wrong

This is an early Phase 1 study in healthy volunteers, not patients. It only checks how the drug is processed, not whether it works for migraines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut, 06511, United States